Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LMAT LeMaitre Vascular	$82.10 -0.6%	$82.81	$71.42 ▼ $109.58	$1.85B	0.82	168,953 shs	135,425 shs
NVCR NovoCure	$16.21 -2.3%	$17.66	$14.17 ▼ $34.13	$1.81B	0.72	1.12 million shs	1.11 million shs
RXST RxSight	$7.38 +1.4%	$13.55	$6.32 ▼ $58.23	$299.90M	1.21	815,759 shs	1.48 million shs
WRBY Warby Parker	$23.45 +2.4%	$20.93	$12.46 ▼ $28.68	$2.45B	2.09	2.00 million shs	1.80 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LMAT LeMaitre Vascular	+0.46%	-2.29%	+0.62%	-4.25%	-5.07%
NVCR NovoCure	-1.19%	-8.80%	-7.37%	+6.48%	-13.95%
RXST RxSight	-2.28%	-8.43%	-48.33%	-49.55%	-85.27%
WRBY Warby Parker	-0.07%	+2.77%	+5.29%	+60.68%	+32.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LMAT LeMaitre Vascular	2.7018 of 5 stars	2.2	1.0	3.3	0.0	3.0	2.5	1.3
NVCR NovoCure	3.4212 of 5 stars	3.4	1.0	0.0	4.5	1.5	1.7	0.0
RXST RxSight	2.2456 of 5 stars	4.0	1.0	0.0	0.0	1.5	1.7	0.6
WRBY Warby Parker	2.4888 of 5 stars	2.3	5.0	0.0	0.0	1.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LMAT LeMaitre Vascular	2.33	Hold	$97.83	19.16% Upside
NVCR NovoCure	2.71	Moderate Buy	$32.43	100.05% Upside
RXST RxSight	1.91	Reduce	$17.50	137.13% Upside
WRBY Warby Parker	2.53	Moderate Buy	$22.88	-2.46% Downside

Current Analyst Ratings Breakdown

Latest RXST, WRBY, NVCR, and LMAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/10/2025	WRBY Warby Parker	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
7/10/2025	WRBY Warby Parker	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00
7/9/2025	RXST RxSight	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/9/2025	RXST RxSight	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$25.00 ➝ $9.00
7/9/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
7/9/2025	RXST RxSight	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LMAT LeMaitre Vascular	$226.26M	8.20	$2.39 per share	34.42	$15.00 per share	5.47
NVCR NovoCure	$605.22M	2.99	N/A	N/A	$3.33 per share	4.87
RXST RxSight	$148.31M	2.02	N/A	N/A	$6.98 per share	1.06
WRBY Warby Parker	$795.09M	3.08	$0.35 per share	67.46	$3.35 per share	7.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LMAT LeMaitre Vascular	$44.04M	$1.98	41.46	37.83	2.17	19.96%	13.53%	9.78%	8/5/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.67	N/A	N/A	N/A	-17.90%	-9.54%	-8.51%	8/7/2025 (Estimated)
WRBY Warby Parker	-$20.39M	-$0.12	N/A	234.53	N/A	-1.79%	-2.48%	-1.29%	8/6/2025 (Estimated)

Latest RXST, WRBY, NVCR, and LMAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	WRBY Warby Parker	$0.09	N/A	N/A	N/A	N/A	N/A
8/7/2025	Guidance Update	RXST RxSight	-$0.0363	N/A	N/A	N/A	$39.78 million	N/A
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	N/A	N/A	N/A	$62.48 million	N/A
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/7/2025	Q1 2025	RXST RxSight	-$0.03	-$0.03	N/A	-$0.20	$38.74 million	$37.90 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LMAT LeMaitre Vascular	$0.80	0.97%	N/A	40.40%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A
WRBY Warby Parker	N/A	N/A	N/A	N/A	N/A

Latest RXST, WRBY, NVCR, and LMAT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LMAT LeMaitre Vascular	0.48	16.49	13.83
NVCR NovoCure	0.27	1.47	1.41
RXST RxSight	N/A	12.68	11.65
WRBY Warby Parker	N/A	2.70	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%
RXST RxSight	78.78%
WRBY Warby Parker	93.24%

Insider Ownership

Company	Insider Ownership
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	5.52%
RXST RxSight	9.57%
WRBY Warby Parker	18.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.45 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable
RXST RxSight	220	40.64 million	36.75 million	Optionable
WRBY Warby Parker	3,780	104.50 million	85.44 million	Optionable

RXST, WRBY, NVCR, and LMAT Headlines

Recent News About These Companies

Warby Parker to Announce Second Quarter 2025 Financial Results August 7, 2025

3 hours ago | businesswire.com

CenterBook Partners LP Invests $1.42 Million in Warby Parker Inc. (NYSE:WRBY)

July 17 at 9:54 AM | marketbeat.com

Head to Head Comparison: Warby Parker (WRBY) & Its Rivals

July 17 at 4:03 AM | americanbankingnews.com

Warby Parker Inc. (NYSE:WRBY) Shares Bought by Bank of New York Mellon Corp

July 16 at 3:39 AM | marketbeat.com

Warby Parker (NYSE:WRBY) Stock Price Up 5.9% - Here's Why

July 14 at 4:02 PM | marketbeat.com

Warby Parker Inc. (NYSE:WRBY) Shares Sold by TimesSquare Capital Management LLC

July 14 at 8:51 AM | marketbeat.com

Contrasting Warby Parker (WRBY) & The Competition

July 14 at 2:55 AM | americanbankingnews.com

Warby Parker (NYSE:WRBY) Cut to Market Perform at Citizens Jmp

July 13, 2025 | americanbankingnews.com

Warby Parker's (WRBY) Market Perform Rating Reiterated at JMP Securities

July 13, 2025 | americanbankingnews.com

JMP Securities Downgrades Warby Parker (WRBY)

July 11, 2025 | msn.com

Warby Parker (NYSE:WRBY) Receives "Market Perform" Rating from JMP Securities

July 10, 2025 | marketbeat.com

Warby Parker (NYSE:WRBY) Stock Rating Lowered by Citizens Jmp

July 10, 2025 | marketbeat.com

Warby Parker Inc. Stock Grades | WRBY - Barron's

July 10, 2025 | barrons.com

Warby Parker Inc. (NYSE:WRBY) Receives $22.88 Average PT from Analysts

July 9, 2025 | americanbankingnews.com

Winners And Losers Of Q1: Warby Parker (NYSE:WRBY) Vs The Rest Of The Beauty and Cosmetics Retailer Stocks

July 8, 2025 | msn.com

Warby Parker Inc. (NYSE:WRBY) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 6, 2025 | marketbeat.com

11,751 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by Diversified Trust Co

July 2, 2025 | marketbeat.com

What Makes Warby Parker (WRBY) an Attractive Investment?

June 30, 2025 | finance.yahoo.com

Bessemer Group Inc. Has $1.17 Million Stock Position in Warby Parker Inc. (NYSE:WRBY)

June 30, 2025 | marketbeat.com

WRBY - Warby Parker Inc Ordinary Shares - Class A Chart - Morningstar

June 28, 2025 | morningstar.comM

The 5 Most Interesting Analyst Questions From Warby Parker’s Q1 Earnings Call

June 27, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST, WRBY, NVCR, and LMAT Company Descriptions

LeMaitre Vascular NASDAQ:LMAT

$82.10 -0.51 (-0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$82.09 -0.01 (-0.01%)

As of 04:20 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$16.21 -0.38 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$16.43 +0.22 (+1.39%)

As of 06:13 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

RxSight NASDAQ:RXST

$7.38 +0.10 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$7.37 -0.01 (-0.19%)

As of 06:29 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Warby Parker NYSE:WRBY

$23.45 +0.55 (+2.41%)

Closing price 03:59 PM Eastern

Extended Trading

$23.47 +0.02 (+0.07%)

As of 06:28 PM Eastern

Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time